CTIS2024-512630-15-00进行中（未招募）1 期
CABRAMET - A phase 2 study of cabozantinib in renal cell carcinoma (mRCC) with brain metastases - ET19-006
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 77
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •I1. Age = 18 years., I10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures., I11. Signed and dated IRB/ICE approved informed consent form., I12. Accepting to use effective contraception (barrier contraceptives) during study treatment and within at least 4 months after final dose of study therapy. Oral contraceptives are not acceptable., I2. Histologically proven mRCC, in first line treatment or after one or two prior treatments., I3. Brain metastases not requiring corticosteroids at dose > 40 mg/day., I4. At least 1 locally untreated brain lesion =8 mm in longest diameter or >5 mm if > 1 lesion., I5. Not previously treated by cabozantinib., I6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 1., I7. Life expectancy = 3 months., I8. Adequate organ function as defined by the following criteria. -Total serum bilirubin <=2 x ULN (Gilbert’s disease exempted) -Serum transaminases and alkaline phosphatases <=2.5 x ULN, or in case of liver or bone metastasis <=5 x ULN -Serum creatinine <=2 x ULN OR creatinine clearance >=50 ml/min -Absolute neutrophil count (ANC) >=1 500/mm3 -Platelets >=100 000/mm3 (100 G/l) -Hemoglobin >=9.0 g/dl., I9. Covered by a medical/health insurance.
排除标准
- •E1. Any local previous treatment of current brain metastases. [Stereotactic radiotherapy or cyberknife on some of the brain metastases is allowed if performed on brain met < 2 cm and at more than 2 weeks before inclusion.], E10. Any acute or chronic medical or psychiatric condition or laboratory abnormality that would make the patient unsuited to study participation., E11. Any second malignancy within the last 3 years with the exception of basal cell carcinoma, in situ cervical cancer and pT1/a bladder cancer with no evidence of recurrent disease for 12 months., E12. Patients receiving strong inhibitor or inducer of CYP3A4 especially some anti-epileptic drugs., E13. Psychological, familial, sociological, geographical conditions that would limit compliance with study protocol requirements., E14. Participation to another clinical trial that might interfere with the evaluation of the main criterion., E15. Known hypersensitivity to the active substance or to any of the excipients., E16. Patient requiring tutorship or curatorship., E2. Any anti-coagulation therapy (except preventive treatment at low dose)., E3. Contra-indication for MRI (i.e. pace-maker)., E4. Uncontrolled seizures., E5. Any symptoms of intracranial hypertension., E6. Any of the following within 12 months prior to treatment initiation: severe/unstable angina, myocardial infarction, coronary artery bypass graft, symptomatic congestive heart failure, ischemic or hemorrhagic stroke including transient ischemic attack., E7. Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic pressure >90 mmHg, despite optimal medical treatment., E8.Ongoing cardiac dysrhythmia of grade >=2, atrial fibrillation of any grade, QTc interval > 0.43., E9. Pregnant or breast-feeding woman (mandatory negative serum or urinary pregnancy test at study entry for all women of childbearing potential).
研究者
相似试验
进行中（未招募）
1 期
Study of cabozantinib in renal cell carcinoma with brain metastasesMetastatic renal cell carcinoma with non locally pre-treated brain metastases, in first line treatment or after one or two prior treatments.EUCTR2019-000678-41-FRCentre Léon Bérard77
进行中（未招募）
1 期
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.CTIS2024-511292-15-00Grupo Espanol De Tumores Neuroendocrinos41
已完成
2 期
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain MetastasesMetastatic Renal Cell CarcinomaNCT03967522Centre Leon Berard26
进行中（未招募）
1 期
Cabozantinib treatment for patients with hepatocellular carcinoma (HCC) refractory to previous treatmentHepatocellular carcinomaEUCTR2019-004126-13-DEniversity Leipzig40
进行中（未招募）
1 期
A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1).Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors.MedDRA version: 21.0Level: PTClassification code: 10073251Term: Clear cell renal cell carcinoma Class: 100000004864CTIS2024-514058-59-00Fondazione IRCCS Istituto Nazionale Dei Tumori49